EDIT (Editas Medicine) Tariff Resilience Score: 8/10 (As of Jun. 30, 2026)


EDIT Editas Medicine Inc EDIT
51 GF Score
Price $3.24
GF Value $1.92
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Editas Medicine Tariff Resilience Score?

Editas Medicine EDIT +1.73% 51 Tariff Resilience Score is 8 as of Jun. 30, 2026. GuruFocus rates EDIT with a GF Score™ of 51/100 and a GF Value™ of $1.92 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,375 Biotechnology companies, Editas Medicine ranks better than 98.69% on this metric.

Editas Medicine has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Editas Medicine has EDIT's operations are primarily research-focused with minimal reliance on international supply chains. The biotech industry often benefits from tariff exemptions, and the company can leverage its pricing power in niche markets to offset potential cost increases.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Editas Medicine might have Highly Resilient.

Editas Medicine  (NAS:EDIT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Editas Medicine Tariff Resilience Score Related Terms

EDIT vs SGMT, AUTL, FBRX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Editas Medicine's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Editas Medicine Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Tariff Resilience Score falls into.


EDIT
51GF Score
Editas Medicine Inc EDIT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Editas Medicine (EDIT) has a Tariff Resilience Score of 8 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Editas Medicine ranks #18 out of 1375 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Editas Medicine's Tariff Resilience Score too high?
Editas Medicine's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Editas Medicine's value of 8 is 100% above this industry median. Based on the distribution chart, Editas Medicine ranks #18 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Editas Medicine has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Tariff Resilience Score compare to SGMT and AUTL?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #18 out of 1375 companies for Tariff Resilience Score. This places Editas Medicine in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Editas Medicine's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Editas Medicine's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Editas Medicine's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.92, compared to a current price of $3.24 — trading 68.5% above its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Editas Medicine's overall GF Score™ is 51/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Tariff Resilience Score is 8 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Editas Medicine (EDIT) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $3.24 is trading 68.5% above its estimated GF Value™ of $1.92. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for EDIT:

  • Tariff Resilience Score: 8
  • GF Value™: $1.92 vs. price of $3.24 (68.5% above fair value)
  • GF Score™: 51/100 with 10 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1375)

No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Other Exchanges 0IFK:UK8EM:Germany
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
51GF Score

Get the complete analysis for EDIT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.24
Price
$1.92
GF Value